ROCHESTER, N.Y., Nov. 8 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. , a leading developer of image-based biomarker solutions, announced today the publication of “Quantitative Imaging in Clinical Trials,” by Chief Scientific Officer Edward Ashton, Ph.D., in the October supplement to Applied Clinical Trials. There is a link to the article on VirtualScopics’ Web site, www.virtualscopics.com.
The article provides a primer on the incorporation of advanced imaging into pharmaceutical and medical device trials. It outlines the tremendous benefits that these techniques can provide to a clinical development program, as well as the pitfalls that can cause an imaging trial to fail.
Applied Clinical Trials is a leading peer reviewed journal servicing the clinical trials market, with an international readership of over 18,000 clinical trials professionals representing major pharmaceutical, medical device and biologics companies; government; medical institutions and other organizations involved in the planning and conduct of clinical trials.
“Incorporating well thought-out medical image acquisition and analysis protocols into clinical trials offers researchers the opportunity to understand drug safety and efficacy earlier in the clinical trial process and with fewer patients,” said Ashton. “This will potentially reduce costs by millions of dollars and speed up development and availability of critical new drugs for disease sufferers worldwide.”
“We’re delighted that Dr. Ashton’s article has been published in Applied Clinical Trials, which not only expands the visibility of the technology for use in clinical trials but continues to reinforce our leadership in this area,” said Jeff Markin, president and CEO of VirtualScopics.
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics’ industry- leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.
CONTACT: Tracy Bagatelle-Black Tim Ryan Bagatelle-Black Trout Group Public Relations Investor Relations 661/263-1842 212 477 9007 x24 tracy@bagatelleblack.comtryan@troutgroup.com
VirtualScopics, Inc.
CONTACT: Tracy Bagatelle-Black of Bagatelle-Black Public Relations,+1-661-263-1842, or tracy@bagatelleblack.com, or Tim Ryan of Trout GroupInvestor Relations, +1-212-477-9007, x24, or tryan@troutgroup.com
Web site: http://www.virtualscopics.com//
